MedTrace Logo

Biomarker for Hereditary AngioEdema Disease

NCT03029728 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2022-03-24

No results posted yet for this study

Summary

International, multicenter, observational, longitudinal monitoring study to identify, validate and/or monitor Mass Spectrometry (MS)-based biomarker/s for Hereditary Angioedeme (HAE) disease and to test the clinical robustness, specificity, and predictive value of theese biomarker/s

Conditions

  • C1 Esterase Inhibitor Deficiency
  • Angio Edema
  • C4 Deficiency
  • HAE
  • Hereditary Angioedema
  • Hereditary Angioedema Type II
  • Hereditary Angioedema Type III
  • Hereditary Angioedema Type I

Sponsors & Collaborators

  • CENTOGENE GmbH Rostock

    lead INDUSTRY

Principal Investigators

  • Peter Bauer, MD · CENTOGENE GmbH

Eligibility

Min Age
2 Months
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2022-03-11
Completion
2022-03-11

Countries

  • Armenia
  • Georgia
  • India
  • Peru
  • Poland
  • Romania
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03029728 on ClinicalTrials.gov